Clinical Trials Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Table 3 Comparison of clinical indexes between the two groups
Characteristic
Follow up (wk)
Control group (n = 38)
TCM group (n = 40)
P value
Urine protein (g/24 h)41.11 ± 1.540.73 ± 1.480.008
120.67 ± 0.910.34 ± 0.820.0159
240.30 ± 0.290.09 ± 0.14< 0.0001
Urine RBC count/HPF417.63 ± 15.489.02 ± 8.780.001
1210.55 ± 9.734.35 ± 8.540.0007
2410.47 ± 8.432.82 ± 5.11< 0.0001
Serum albumin (g/L)434.60 ± 6.5736.36 ± 4.910.324
837.27 ± 6.6439.35 ± 3.820.428
1239.65 ± 6.7341.16 ± 3.990.701
1640.26 ± 6.4541.17 ± 5.020.879
2041.50 ± 5.1641.08 ± 7.000.821
2440.30 ± 6.2841.15 ± 5.140.808
Serum C3 (g/L)40.61 ± 0.140.53 ± 0.190.112
80.73 ± 0.160.69 ± 0.250.205
120.80 ± 0.190.73 ± 0.0.210.143
160.82 ± 0.150.77 ± 0.200.452
200.82 ± 0.150.85 ± 0.140.874
240.88 ± 0.170.86 ± 0.220.990
Serum C4 (g/L)40.10 ± 0.040.08 ± 0.050.800
80.12 ± 0.050.11 ± 0.050.730
120.14 ± 0.070.10 ± 0.050.122
160.15 ± 0.060.13 ± 0.050.235
200.16 ± 0.060.14 ± 0.060.874
240.18 ± 0.070.18 ± 0.230.624
SCR (μmol/L)444.75 ± 19.1042.65 ± 12.860.768
844.18 ± 19.1044.02 ± 13.080.794
1259.08 ± 76.3245.17 ± 14.430.244
1646.53 ± 11.7048.81 ± 14.680.922
2049.46 ± 12.4749.38 ± 14.090.939
2450.11 ± 9.5845.40 ± 10.320.060
BUN (IU/mL)46.93 ± 2.606.08 ± 2.010.135
86.24 ± 3.135.46 ± 2.040.492
125.20 ± 1.865.39 ± 1.610.654
165.04 ± 1.385.04 ± 1.600.975
204.93 ± 1.424.67 ± 1.430.469
244.88 ± 1.244.34 ± 1.380.051
Dosage of GCs055.05 ± 7.4452.70 ± 10.940.683
452.94 ± 6.3846.79 ± 12.720.098
847.67 ± 6.4440.78 ± 12.110.011
1243.58 ± 6.3235.14 ± 12.77< 0.0001
1639.14 ± 5.3830.62 ± 9.870.0001
2034.64 ± 5.0425.74 ± 8.840.060
2431.44 ± 4.8517.61 ± 7.45< 0.0001
ds-DNA positive, n (%)2410 (26.3)9 (22.5)0.694
SLEDAI411.00 ± 5.219.02 ± 4.020.073
127.16 ± 3.526.58 ± 3.640.625
245.67 ± 4.275.12 ± 3.480.990